Respiratory diseases such as chronic obstructive pulmonary disease [COPD], severe asthma, cystic fibrosis [CF] and idiopathic pulmonary fibrosis [IPF] are inadequately controlled by current therapies. The underlying molecular mechanisms and pathogenesis of these diseases remain unclear, making identification and validation of potential new therapeutic targets difficult. However, recent studies have identified the central signalling mediator PI3K as playing an integral role in the immune system including initiation and maintenance of inflammatory responses. Specifically, the relatively leukocyte-specific PI3Kg and PI3Kd isoforms are central to leukocyte function and can be targeted pharmacologically. Early to man studies using selective PI3K isoform inhibitors are required to determine whether they have a future in treating respiratory disease, particularly in controlling both innate and adaptive inflammatory responses as well as restoring glucocorticoid function and reducing tumorigenesis.
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Therapeutic needs in respiratory disease: targeting inflammation Chronic inflammation is associated with many respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF) [Barnes 2008a [Barnes , 2008b Nichols et al. 2008; Chung et al. 2002] . While current anti-inflammatory therapies such as glucocorticoids are effective at controlling inflammation in a number of diseases, their function is markedly reduced in others such as in COPD, CF and in patients with severe asthma [Barnes and Adcock, 2009] . Importantly the pathogenesis of these diseases is poorly understood and therefore identification and development of viable alternative anti-inflammatory therapies have proven difficult. Similarly, the underlying pathogenesis of IPF remains unclear and current treatments ineffective; however, the role of inflammation in this disease remains controversial [Bringardner et al. 2008] .
The relative ineffectiveness of glucocorticoid treatment in these diseases along with a lack of effective anti-inflammatory alternatives results in extensive disease management problems, frequent hospitalisation and cost burden for healthcare systems worldwide. This lack of current effective anti-inflammatory therapies for many of these diseases may underlie the failure in halting disease progression and ultimately in reducing mortality. The search for new therapeutic targets including effective anti-inflammatory agents has led to the consideration of a plethora of kinases as targets since many of these kinases such as the lipid kinase phosphatidylinositol 3-kinase (PI3K) are important in regulating receptor-mediated signalling and cellular function. Indeed, a growing number of studies have shown that selective targeting of individual PI3K isoforms is a potential therapeutic strategy for the control of inflammation, including that seen in respiratory diseases.
PI3K families and signalling
PI3Ks are intracellular signalling proteins that are involved in orchestrating a plethora of fundamental cellular functions including growth, proliferation, migration and metabolism [Engelman et al. 2006; Cantley, 2002] . PI3Ks function as heterodimers formed of a catalytic subunit and a regulatory subunit and are predominantly involved in the initiation of receptor-mediated signalling cascades by phosphorylating phosphoinositol lipids which act as secondary messengers for a diverse array of downstream signalling cascades [Vanhaesebroeck et al. 2001] .
The PI3K family are divided into three subtypes [class I, II and III], based on their structure, phospholipid substrate and mode of regulation. The class I PI3Ks can be further subtyped depending on their associated catalytic subunit into class IA (p110a, p110b and p110d) and class IB (p110g). Class IA are activated by cell surface expressed receptor tyrosine kinases (RTKs) such as growth factors, insulin and cytokines, while class IB are activated by G-protein coupled receptors (GPCRs). The signalling pathways regulated by class 1 PI3K signalling are central in many of the fundamental cellular processes associated with PI3K signalling including growth, proliferation, migration and survival [Cantley, 2002] ( Figure 1 ).
The catalytic subunits of the class IA PI3Ks form heterodimers with one of five Src-homology 2 (SH2) domain-containing regulatory subunits; p85a, p85b, p55a, p55g and p50a which bind with high affinity to phosphorylated tyrosines of RTKs. PI3Ka and b are ubiquitously expressed while the expression of PI3Kd is restricted to leukocytes. The single class 1B catalytic isoform p110g binds to either p101 or p84/p87 adaptors, which function to potentiate activation by bg-subunits of heterotrimeric GTP-binding proteins which facilitate intracellular signalling from GPCRs. Similarly to PI3Kd, PI3Kg expression is largely restricted to leukocytes, although expression has also been detected in the endothelium and the heart [Wymann and Marone, 2005] . cytosolic plasma membrane which serves as a docking site for proteins with pleckstrin-homology (PH)-domains such as PKB/Akt leading to the regulation of a diverse array of signalling cascades and cellular function. This process is negatively regulated by phosphatase and tensin homolog (PTEN) which converts PI(3,4,5)P 3 back to PI(4,5)P 2 or SH-2 domain containing inositol phosphatase (SHIP) which converts PI(3,4,5)P 3 to PI(3,4)P 2 . However, since all the class I PI3Ks generate PI(3,4,5)P 3 , it is intriguing why selective pathways or stages in pathways may be mediated by PI(3,4,5)P 3 generated by a specific isoform rather than an indiscriminate activation of a number of pathways that are regulated by PI(3,4,5)P 3 . Recent reports now indicate that the signalling pathways may be able to discriminate between PI(3,4,5)P 3 s generated by different PI3Ks depending on their adapter proteins [Balla, 2009; Bohnacker et al. 2009 ].
The class II PI3Ks consist of three isoforms (C2a, C2b and C2g) and are widely expressed. Class II PI3Ks are able to phosphorylate phosphoinositol (PI) and phosphoinositol 4-monophosphate (PI[3]P) in vitro as well as binding to PI(4,5)P 2 and PI(3,4)P 2 ; however; their exact in vivo substrate(s) remain unknown. Their exact function also remains unclear, although a role in the regulation of vesicular transport directed to the trans-Golgi network has been reported [Gaidarov et al. 2005] . There is also a growing list of stimuli able to activate class II PI3Ks including chemokines such as CC chemokine ligand 2 (CCL-2), cytokines such as leptin and TNFa, lysophosphatidic acid (LPA), insulin as well as growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and stem cell factor (SCF) via association with their receptors [Falasca et al. 2007 ].
Class III PI3K consists of a single family member vacuolar protein sorting mutant 34 protein Vps34p which is associated with Vsp15 (also known as p150) and appears to be important in endocytosis and vesicular trafficking [Burda et al. 2002] . Class III PI3Ks have also been implicated in Toll-like receptor (TLR) signalling [Kuo et al. 2006 ].
PI3K isoforms in inflammation, immunity and cancer
Of all the PI3Ks, the class 1 PI3Ks (PI3Ka, b, g and d) have been the most extensively studied. As the class I PI3K are central to cell growth and proliferation, individual isoforms have consequently been strongly linked with the regulation of oncogenes and tumorigenesis [Samuels and Ericson, 2006] . PI3Ka is upregulated and/ or mutated in a variety of carcinomas, and in particular lung tumours, and is associated with an elevation in activation and signalling of the serine-threonine kinase Akt [Carson et al. 2008; Kang et al. 2005 ]. This elevation of PI3K-Akt signalling plays a key role in the survival, proliferation and invasive potential of tumour cells and is therefore a potential target in carcinomas, including lung cancer . The ubiquitous expression of PI3Ka and b coupled with their involvement in a range of the fundamental cellular processes is likely to exclude therapeutic targeting of these isoforms for indications outside oncology or acute therapeutic use.
In contrast, PI3Kd and PI3Kg have a more restricted, although not exclusive expression in leucocytes [Wymann and Marone, 2005] . In addition to isoform selective small molecule inhibitors, transgenic mice which are devoid of either PI3Kg or PI3Kd signalling have been developed to assess the roles of these isoforms in immune cells and immunity in vivo [Okkenhaug, 2002; Hirsch et al. 2000] (Figure 2 ). PI3Kg knockout mice (PI3Kg À/À ; devoid of the catalytic p110 subunit of PI3Kg) display reduced thymocyte survival and T cell maturation including a significant reduction in CD4 + cells [Sasaki et al. 2000 ]. In addition, PI3Kg À/À demonstrated the importance of PI3Kg signalling in GPCRmediated responses in inflammation with reduced neutrophil activation in response Nformyl-Met-Leu-Phe [fMPL] and complement component C5a and mast cell activation by IgE correlating with an absence of PI(3,4,5)P 3 generation and Akt activation [Hirsch et al. 2000; Sasaki et al. 2000] . Similarly, macrophage migration to the site of inflammation is also diminished in PI3Kg À/À mice [Hirsch et al. 2000 ].
Genetic abolition of PI3Kd signalling by insertion of a kinase-dead p110d catalytic subunit [PI3Kd D910/A910 ] results in impaired B cell and T cell antigen receptor signalling [Okkenhaug, 2002] . PI3Kd D910/A910 mice also display impaired B cell development and differentiation including a reduction in B cell progenitor cells and an increase in the ratio of pre-(CD43 À IgM + ) to pro-(CD43 + IgM À ) B cells [Okkenhaug, 2002] . T cell differentiation into Th1, Th2 and Treg lineages are also impaired in the PI3Kd D910/A910 mice by a mechanism involving reduced T cell receptor activation of Akt and FOXO Okkenhaug, 2002] . In addition, IgE-FceR1 mediated degranulation of mast cells is abolished in PI3Kd D910/A910 mice [Ali et al. 2004 ].
These transgenic mice, along with studies using isoform selective PI3K inhibitors, clearly demonstrate that PI3Kd and PI3Kg are integral in the orchestration of both the innate and adaptive immune response including leukocyte migration, activation, B and T cell maturation and antigen response [Fruman and Bismuth, 2009; Kok et al. 2009; Wymann and Schneiter, 2008; Rommel et al. 2007] (Figure 2 ). Therefore given the role of PI3Ks in immune cells in addition to both the favourable expression of PI3Kd/g and the ability to deliver therapies locally to the lung, selective PI3Kg and d inhibitors are attractive targets for a new anti-inflammatory therapy in respiratory disease (Figure 3 ).
Asthma
The allergic inflammatory response in asthma is characterised by the activation and degranulation of tissue mast cells and recruitment of eosinophils into the lung [Barnes, 2008a; Galli et al. 2008; Trivedi, 2007] . Last cells are a key source of inflammatory mediators and may thereby regulate airway smooth muscle function [Siddiqui et al. 2007 ]. Allergen-induced B cell production of IgE is an important component of allergic diseases including asthma by induction of mast cell degranulation through high-affinity FceR1 receptor signalling [Gould and Sutton, 2008] . Degranulation of mast cells is largely responsible for sustaining the allergic reaction through the release of several pro-inflammatory and bronchoconstrictive mediators (including histamine, proteoglycans and serine proteases) and thereafter the synthesis of further inflammatory mediators (including prostaglandin D2, cysteinyl leukotrienes and eosinophil chemotactic factor) [Hakim-Rad et al. 2009; Boyce et al. 2009 ]. The subsequent the recruitment of eosinophils in allergic inflammation provides a key source of cytotoxic proteins, lipid mediators, reactive oxygen species and cytokines which contribute to disease severity [Boyce et al. 2009; Chung and Barnes, 1999] .
Importantly, PI3K signalling is integral to both mast cell and eosinophil function [Boyce et al. 2009; Kim et al. 2008 ]. Inhibition of PI3K signalling with the nonselective inhibitor LY294002 in an ovalbumin (OVA)-challenged murine model of asthma reduced inflammatory cell influx into the lung as well as reduction of IL-5, IL-13 and CCL11 (eotaxin) [Duan et al. 2005 ]. In addition, tissue eosinophilia, airway mucus production and airway hyper-responsiveness [AHR] to inhaled metacholine were all suppressed. These results are supported by other studies where pharmacological inhibitors of PI3K or adenoviral-mediated PTEN overexpression all reduced eosinophilia and AHR in models of allergen challenge [Kwak et al. 2003; Ezeamuzie et al. 2001] . Collectively, these studies clearly demonstrate that direct targeting of PI3K in the lung reduces allergic inflammation. However, these studies use nonselective PI3K inhibitors (LY294002 and Wortmannin) which also target PI3Ka and b isoforms and may result in toxicological problems when used for long periods. Therefore, it is essential to determine the roles of the PI3Kg and d isoforms in allergic inflammation which may offer a potentially more viable avenue for therapeutic targeting.
Pharmacological inhibition of PI3Kd using the selective PI3Kd inhibitor IC87114 in models of allergic inflammation show similar results to pan-PI3K inhibition; including attenuated vascular leakage, tissue eosinophilia, airway mucus production, and AHR as well as release of cytokines (IL-4, -5 and -13), chemokines (CCL5, CCL11) and adhesion molecules (ICAM-1, VCAM-1) [Lee et al. 2006a [Lee et al. , 2006b ]. These results are supported by the well-documented role for PI3Kd in B and T cell antigen receptor signalling through the high-affinity IgE receptor FceR1, including mast cell activation and degranulation determined using both pharmacological and genetic approaches [Ali et al. 2008 [Ali et al. , 2004 Puri, 2004] . However, the role of PI3Kd in IgE responses may be more complex than simply blocking FceR1 signalling. Pharmacological inhibition of PI3Kd using the selective inhibitor IC87114 has been shown to attenuate OVA-stimulated systemic IgE levels [Lee et al. 2006a ]. However, a recent report has shown that inhibition of PI3Kd by both genetic abolition and pharmacological intervention reduces both allergen induced Th2 cytokines and IgG but paradoxically elevates systemic IgE levels . Here it is proposed that PI3Kd may be involved in the regulation of B cell class switching from IgG to IgE production despite severely 
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Pro-resolution: [Wymann et al. 2003 ]. Taken together, these studies clearly show that selective pharmacological inhibition of PI3Kd/g isoforms is a potential therapeutic strategy for suppressing allergic inflammation in asthma.
However, although the recruitment of eosinophils in the airways is an important component of asthma, the trafficking of T lymphocytes into the airways is now believed to be central in the establishment and orchestration of the allergic inflammatory response in asthma [Afshar et al., 2008] . A reduction in specific T cell subtype recruitment and/or activation may therefore be beneficial in controlling the progression of the allergic response in asthma. PI3K is essential to T cell survival where mice lacking both PI3Kg and PI3Kd display T cell lymphopenia with diminished CD4 + /CD8 + cells associated with T cell depletion in the blood and secondary lymphoid organs Swat et al. 2006 ]. Dendritic cells from PI3Kg knockout mice have impaired migration and are defective in T cell mediated immune responses [Del Prete et al. 2004 ]. Furthermore, Abolition of PI3Kg, but not PI3Kd, signalling impairs thymocyte development and T cell migration towards lymphoid chemokines CCL19, CCL21 and CXC chemokine ligand 12 (CXCL12) [Reif et al. 2004; Hirsch et al. 2000; Sasaki et al. 2000 ].
In contrast, specific impairment of PI3Kd signalling by either kinase-dead knock-in or specific PI3Kd inhibition leads to T cell lymphopenia, elevated IgE levels and alters T cell function through impairment of Th1 and Th2 differentiation and a reduction in the clonal expansion of CD4 + T cells in response to antigen challenge Okkenhaug et al. 2006; Okkenhaug, 2002] . Mice expressing a mutant PI3Kd kinasedead isoform also have reduced natural killer (NK) T cell maturation and cytotoxicity which are important in the amplification of both the innate and adaptive immunity and may be important in underlying the disease severity of asthma [Rock et al. 2009; Guo et al. 2008] . In addition to impaired T cell development, PI3Kd kinase-dead mice show a reduction in B cell development, activation and formation of germinal centres and chemotaxis to CXCL13 Ali et al. 2004; Reif et al. 2004; Okkenhaug, 2002] . Inhibition of PI3Kd results in impaired also B cell and T cell antigen receptor signalling, including B cell receptor-mediated antigen presentation [Puri et al. 2005; Okkenhaug, 2002; Clayton et al. 2002] .
Taken together, these studies show that abolition of PI3Kd and g signalling significantly reduces the inflammatory response in the lungs of models of allergic inflammation and asthma. Consequently, a variety of small molecule inhibitors of these isoforms are already in development for allergic disease ]. However, the potential therapeutic advantages of PI3Kd/g inhibition on reduced T cell infiltration and B cell receptor-mediated antigen presentation may be eclipsed by potential negative effects on peripheral tolerance, altered IgE levels and toxicological hurdles (discussed later).
Severe asthma
Around 5% of asthmatics develop severe asthma which has an immunological profile with more similarities to COPD as compared with mild/ moderate asthma; including increased neutrophils, CXCL8 and TNFa [Barnes, 2008a] . Furthermore, whereas Th2 cells predominate in mild/moderate asthma, severe asthma displays a mixture of both Th1 and Th2 cells and an elevation in CD8 + cells, which is also seen in COPD. Current therapies such as long-acting beta agonists and glucocorticoids are often inadequate of controlling the disease, and in particular the acute neutrophilia-associated exacerbations [Jarjour et al. 2006 ]. Consequently, although severe asthma only accounts for around 5% of asthmatics it accounts for more than half of the healthcare spending on asthma [Wenzel and Busse, 2007] . These patients with severe asthma demonstrate persistent airway inflammation, with relative corticosteroid insensitivity as demonstrated ex vivo in blood monocytes and lung macrophages [Bhavsar et al. 2008; Hew et al. 2006; Jatakanon et al. 1999] . Although the role of PI3K signalling in severe asthma has not been assessed in any great detail, there is strong evidence that selective targeting of the PI3Kd and g isoforms reduces immunological responses akin to both mild/moderate asthma and COPD (discussed below) and may therefore be considered a potential anti-inflammatory therapeutic strategy for the treatment of these patients.
A significant driving force behind the enhanced and persistent inflammation in the lungs of severe asthmatics is an inability of the inflammation to resolve and thereby self regulate. This is also likely to be an integral factor in COPD where even after the removal of the exogenous driving force (predominantly cigarette smoke) the inflammatory response continues. Interestingly, in addition to their role in initiation of both innate and adaptive immune responses, PI3Ks may also play an important role in the resolution of inflammation. The resolution of allergeninduced eosinophilic inflammation is enhanced by inhibition of PI3K by a mechanism involving blockade of Akt activation and enhanced cell apoptosis [Pinho et al. 2005 ]. The removal of apoptotic and damaged cells by phagocytosis is also a process central to the promotion of inflammatory resolution [Hallett et al. 2008; Serhan and Savill, 2005] . Studies using both transgenic mice and selective inhibitors have demonstrated that PI3Kb is required for functional Fcg receptor-mediated macrophage phagocytosis [Leverrier et al. 2008] . Therefore, in addition to their anti-inflammatory action, PI3K inhibitors may also promote inflammatory resolution and thereby may provide an additional therapeutic benefit.
Chronic obstructive pulmonary disease COPD is characterised by airflow obstruction that is both progressive, largely irreversible and associated with remodelling of the small airways and an enhanced chronic inflammation in the lung [Barnes, 2008a; Chung and Adcock, 2008] . This chronic inflammatory response is thought to be central to the development and progression of the disease. In contrast to asthma, the inflammation is present in the small airways and parenchyma as well as in the larger airways and is also immunologically distinct; involving primarily innate/Th1 immunity including recruitment of neutrophils, macrophages, T helper 1 [Th1] and Type 1 cytotoxic T (Tc1) cells [Barnes, 2008a; Chung and Adcock, 2008] . This chronic inflammation in COPD is orchestrated by a complex milieu of pro-inflammatory mediators; include chemokines such as CCL2, CXCL1 and CXCL8-11, cytokines such as TNFa, IL-1b, IL-6 and INFg and proteases such as neutrophil elastase and metalloproteinase 9 [Barnes, 2008b] . Crucially, both this chronic enhanced inflammation and the acute episodes or exacerbations of the condition are relatively poorly controlled by glucocorticoids or other anti-inflammatory alternatives [Barnes and Adcock, 2009] .
As for severe asthma, relatively less direct experimental work has been performed examining a role for PI3K in chronic elevated inflammation in COPD compared to the numerous studies surrounding models of allergic airways inflammation. However, due to the influential role of PI3K in inflammation along with a central role in the activation and function of many of the inflammatory cells implicated in the pathogenesis of COPD, there is growing evidence for PI3Ks as a valid therapeutic target for this disease.
Neutrophils and macrophages are recognised as key inflammatory cells in COPD, with neutrophils being particularly important in exacerbations of the disease. PI3K activation is important for neutrophil migration through accumulation of PI(3,4,5)P 3 at the leading edge of the migrating cell contributing to asymmetric F-actin synthesis and cell polarisation [Heit et al. 2008; Sadhu et al. 2003b ]. PI3K appears to be indispensible for CXCL8, but not for fMLPmediated neutrophil migration indicating chemoattractant specificity of this response [Heit et al. 2008] . Several studies, both in vitro and in vivo, initially ascribed the PI3K-dependent component of migration to PI3Kg, but PI3Kg inhibition has little impact on chemokinesis although cells lack directionality in response to GPCR-mediated stimuli [Ferguson et al. 2007; Sasaki et al. 2004; Wang et al. 2002; Hirsch et al. 2000; Sasaki et al. 2000; Naccache et al. 2000 ]. Other studies, however, have shown a role for PI3Kd in determining the directionality of neutrophil chemotaxis [Sadhu et al. 2003b] . It is likely that PI3Kd accelerates polarisation whilst PI3Kg accelerates orientation of migrating neutrophils. Macrophage numbers are also significantly elevated in COPD, through recruitment and thereafter differentiation of monocytes from the peripheral blood. Monocyte infiltration into the lung may also be PI3K-dependent as b1and B2-integrin mediated monocyte adhesion and migration, spreading and diapedesis is impaired by wortmannin, LY294002 and the PI3Kd selective inhibitor IC87114 [Ferreira et al. 2006 ]. Pharmacological inhibition of PI3Kd/g may therefore present an attractive therapeutic strategy to reduce both neutrophil and monocyte recruitment to the lungs in COPD.
Neutrophil activation and respiratory burst also involves class I PI3K signalling. Studies have implicated both PI3Kg and PI3Kd in regulating fMLP-mediated neutrophil activation and respiratory burst [Sadhu et al. 2003a; Li et al. 2000; Sasaki et al. 2000; Hirsch et al. 2000 ]. However, it has now been proposed that fMLP-mediated release of reactive oxygen species (ROS) in human neutrophils requires both PI3Kg and PI3Kd activation in a biphasic manner [Condliffe et al. 2005] . Thus, the initial phase is largely PI3Kg-dependent with the later PI3Kddependent phase dependent upon the initial PI3Kg activation. PI3K may also regulate NADPH-dependent superoxide production in fMLP-stimulated monoyctes [Poolman et al. 2005 ].
In addition to neutrophils and macrophages, Th1 and Tc1 cells are also involved in the orchestration and progression of the chronic inflammatory response seen in COPD. Interestingly, T cell trafficking is heavily linked to PI3K signalling as is the recruitment and retention of specific T cell types such as Tc1 cells by mechanisms involving the T cell antigen receptor [TCR] and costimulatory molecules such as cytotoxic T lymphocyte antigen-4 [CTLA-4] [Ward and Marelliberg, 2009] . The therapeutic potential of PI3K
inhibitors has yet to be fully investigated but presents an exciting and potentially important therapeutic strategy.
One of the major concerns of COPD, as with severe asthma, is that the inflammatory response is relatively unresponsive to glucocorticoids. Importantly, we recently identified a potential role for PI3Kd in restoring glucocorticoid responsiveness in a model of cigarette smokeinduced glucocorticoid insensitivity in PI3Kg kinase dead transgenic mice [Marwick et al. 2009 ]. This may be of particular therapeutic interest given the potential toxicity and tolerance hurdles facing PI3Kg as an anti-inflammatory therapeutic target (discussed later).
Cystic fibrosis
In addition to asthma and COPD, pharmacological targeting of PI3K isoforms may also be applied to other respiratory diseases. CF is caused by a mutation in the gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) and is one of the most common lethal genetic diseases in Caucasians [O'Sullivan and Freedman, 2009] . CFTR is expressed in epithelial cells and leukocytes and acts mainly as a chloride channel, although it has a plethora of other key regulatory functions including regulation of ATP channels, intracellular vesicle transport, acidification of intracellular organelles and inhibition of both epithelial sodium channels and endogenous calciumactivated chloride channels [O'Sullivan and Freedman, 2009] .
The lungs of children with CF appear normal at birth, but then rapidly become infected and inflamed with an influx of polymorphonuclear cells. This is associated with an imbalance in pro-and anti-inflammatory mediators including an elevation in NF-kB signalling, IL-6, CXCL8, TNFa and ecosanoid expression whilst the levels of anti-inflammatory mediators such as IL-10, lipoxin and docosahexaenoic acid are reduced [O'Sullivan and Freedman, 2009; Carrabino et al. 2006; Freedman et al. 2004; Karp et al. 2004] . The inflammatory component of CF is important, yet current therapies are ineffective. Ibuprofen is the recommended anti-inflammatory therapy as it is inexpensive, has relatively few side effects and has been shown to be beneficial when given before the onset of severe inflammation and pathological changes in the lung [Konstan, 2008] .
Glucocorticoids are relatively ineffective in CF and are not used due to the unacceptably high side effect profile seen with the high doses of oral glucocorticoids often prescribed. Therefore there is an acute lack for effective anti-inflammatory alternatives for use in CF. Recent studies have shown that PI3K is central in the regulation of cAMP-and cGMP-induced duodenal epithelial CFTR channel activity and intracellular trafficking; however, the isoforms responsible for this have not been elucidated [Tuo et al. 2009] . No studies have as of yet investigated the potential therapeutic impact of specific PI3Kd or PI3Kg inhibitors in CF. However, a PI3Kd/g mediated reduction in the influx of pro-inflammatory cells, as shown in a range of inflammatory models, may provide a possible alternative anti-inflammatory strategy. However the roles of these isoforms in other aspects of the disease, in particular the regulation of CFTR channel, must be elucidated first.
Idiopathic pulmonary fibrosis
Fibrotic lung diseases such as IPF are characterised by a progressive decline in lung function and premature death from respiratory failure [Mehrad et al. 2008] . The role of inflammation in such diseases remains controversial as there is no large influx of inflammatory cells into the lung that would be expected with either an innate or adaptive immune response, as seen in asthma and COPD. However, circulating fibrocytes (progenitor cells derived from the bone marrow) traffic into the lung and contribute to the fibrosis and progression of the disease. This fibrocyte influx is dependent on stromal cell derived factor-1 (CXCL12) signalling through CXCR4 which is the predominant chemokine receptor on fibrocytes [Mehrad et al. 2008 ]. CXCR4 expression is elevated by growth factors and hypoxia (HIF-1a), which is prevented by PI3K inhibition with LY2949002; however, the specific isoform[s] responsible for this remain unknown [Mehrad et al. 2008 ]. In addition, inhibition of the mammalian target of rapamycin (mTOR) by rapamycin abolishes fibrocyte infiltration into the lung and substantially reduces both fibroctye CXCR4 expression collagen deposition in the lungs of bleomycin-challenged mice [Mehrad et al. 2008] . This provides evidence that pharmacological inhibition of the PI3K/Akt/mTOR pathway may provide a potential therapeutic strategy for fibrosis in IPF. In addition, the PI3K pathway is further implicated in the proliferation of fibrocytes seen in IPF. Specifically, polymerised type I collagen limits fibrosis proliferation thereby preventing uncontrolled fibrosis after injury by a mechanism that involves suppression of PI3K signalling through elevated PTEN activity which is a negative regulator of PI3K. However, fibrocytes from IPF lack this restraint due to low PTEN activity resulting in elevated PI3K signalling [Xia et al. 2008] . Targeting the PI3K pathway may provide therapeutic benefit in patients whose disease to date has often been considered irreversible and untreatable.
Lung cancer PI3K-mediated signalling may be involved in oncogenesis and has been linked to the development of several carcinomas, particularly in the lung [Engelman, 2009; Vogt et al. 2009; Liu et al. 2009; Kang et al. 2005] . There is also a strong association between lung cancer and COPD which is independent of smoking [Kiri et al. 2009; van Gestel et al. 2009; Young et al. 2009 ]. This is of particular importance when considering therapeutic applications where treatment of one condition may impact on the other. PI3K-mediated oncogenic transformation acts through Akt and mTOR and is dependent on PI(3,4,5)P 3 formation by the class 1 PI3Ks [Denley et al. 2009 ]. PI3Ka is the isoform most predominantly associated with lung cancer. Elevated expression and/or mutations in the PIK3CA gene result in elevated RTK function, activation of Akt and loss of function of the tumour suppressor and negative regulator of PI3K PTEN Kang et al. 2005; Samuels et al. 2005] . However recently, a role for PI3Kb in oncogenesis has been established ]. Two seminal studies using conditional knockouts for PIK3CB (p110b gene) and kinase inactive p110b (p110b-K80R5) mice showed that impairment of functional p110b activity is protective against tumour formation [Ciraolo et al. 2008; Jia et al. 2008 ].
Due to the apparent importance of this PI3K-Akt-mTOR pathway in tumour development, several nodes of the pathway are prominent targets for anticancer therapy including Akt and mTOR inhibitors. Although mTOR was only recently identified as a member of the PI3K pathway, it is the first 'node' of the pathway fully developed and introduced into the clinic [Faivre et al. 2006 ]. However, although mTOR inhibitors improve survival in certain cancers such as renal cell carcinoma, they appear less effective in many other tumour types [Faivre et al. 2006 ]. A range of Akt inhibitors are currently in development whose mechanisms centres around blockade of ATP binding [Lindsley et al. 2007 ]. However, recent evidence suggests that prevention of ATP binding by this manner results in Akt recruitment to cell membrane and activation via alterative mechanisms [Okuzumi et al. 2009 ]. This action need to be investigated in oncogenic signalling and tumour development and may therefore require the development of Akt inhibitors with an alternative mechanism of action. Therefore, as PI3Ks are integral in the activation of Akt, use of a pan or PI3Ka/b selective inhibitors may offer an alternative to direct inhibition of Akt. However the development and potential application of selective PI3Ka/b or pan-Pi3K inhibitors must be considered with the likely toxicological complications, particularly as both PI3Ka and b play a central role in cell growth and proliferation. This is highlighted by the role of PI3Ka in metabolic diseases where abolition of PI3Ka signalling impairs insulin and insulin like growth factor-1 leading to growth retardation, hyperinsulinaemia, glucose intolerance, hyperphagia and increased adiposity [Foukas, 2006] . However, if toxicological profiles are acceptable, then PI3K inhibitors may provide a successful therapy against the key PI3K-Akt-mTOR signalling pathway in cancers including lung cancer. In addition, with the increasing evidence of comorbidity between lung cancer and COPD, acute use of a broad spectrum PI3K inhibitor, if tolerated, may provide not only an effective anti-inflammatory treatment but also a treatment for the regression of the lung cancer.
Pitfalls and hurdles: which way to target?
Both PI3Kd and PI3Kg appear to have important roles in mast cell degranulation induced by crosslinking of the high-affinity IgE FceRI receptor. However, a recent study looking at their relative importance in vivo using transgenic mice concluded that PI3Kd but not g was required for optimal IgE-dependent hypersensitivity responses [Ali et al. 2008] . Migration and recruitment of inflammatory cells such as eosinophils may also be stimulus-dependent [Mishra et al. 2009 ]. It can be reasonably concluded that in a stimulus-specific response, or in a disease which is mediated by a predominant stimulus [such as IgE], inhibition of one of these isoforms over the other may prevail. However, despite their structural and functional differences, it is now also apparent that both PI3Kd and g can be involved in regulating the same response. This has highlighted TNFa/fMLP-induced respiratory burst in human neutrophils which requires sequential activation PI3Kd and g [Condliffe et al. 2005] . The initial response is PI3Kgmediated; however, the amplification of the response is predominantly mediated by PI3Kd and may be viewed as a 'positive feedback' response [Condliffe et al. 2005] . This is in contrast to murine neutrophils where the respiratory burst appears to be predominantly dependant on PI3Kg activation, providing evidence of species difference and highlighting the need for more investigations in primary human cells. Similarly, both PI3Kd and g have been implicated in the regulation of mast cell degranulation.
In conditions such as COPD, CF and severe asthma where there is a predominance (or at least a major component) of an innate/Th1 inflammatory response, again there is clear evidence for both PI3Kd and g involvement in neutrophil, monocyte and T cell activation and recruitment. However, given the complexities and lack of understanding of the underlying pathogenesis of these diseases, it may be more prudent to look towards dual PI3Kd-g inhibitors as well as selective inhibitors of the individual isoforms.
A major determinant in the development of and ultimately application of selective PI3K inhibitors in disease will be based on their toxicity and tolerance profiles. The potential side effect profile of selective PI3Kg inhibitors is theoretically minimal based on the phenotype of genetic mutants and its restricted expression. However, studies using both PI3Kg knockouts and the selective PI3K inhibitor AS-605240 demonstrate that animals devoid of functional PI3Kg activity display a reduced host response to Streptococcus pneumoniae infection demonstrated by reduced macrophage recruitment and survival [Maus et al. 2007 ]. In addition, PI3Kd kinase dead mice also have a reduction in B cell development, activation and formation of germinal centres and chemotaxis to CXCL13 Ali et al. 2004; Reif et al. 2004; Okkenhaug, 2002] . A significant impairment of B cell function may compromise the ability of the immune system to deal with infection, thereby increasing the risk of developing consequent serious bacterial or viral infection. These effects may pose a potentially serious complication both in asthma, where there is a reduced lung immune response to infections, and in COPD, where lung infections have been associated with the severity and progression of the disease [Wilkinson et al. 2006; Murray et al. 2006 ]. Conversely, formation of B cell germinal centres in COPD may be associated with autoimmune responses which may be important in driving severe disease [Cosio et al. 2009 ].
Inhibition of PI3Kd and g may provide a beneficial therapeutic strategy for the reduction of Th1/ Th2 and Tc1 cells in respiratory disease; however, other T cells [including CD4 + CD25 + regulatory T [Treg] cells] may be important in the resolution of established allergic airway inflammation along with mucus hypersecretion and airway remodelling [Kearley et al. 2008; Lewkowich et al. 2005] . Although the role of PI3K signalling in the development and function of Treg cells is unknown, any impairment may lead to adverse immune responses. It is also noteworthy that functional inhibition of PI3Kd in transgenic kinase-dead mice leads to the retention of Foxp3 + T regulatory cells in the thymus and consequent loss of peripheral tolerance ]. Indeed, Foxp3 + T regulatory cells have a well-established role in the maintenance of peripheral tolerance and control of immune responses ]. Furthermore, if PI3Kd inhibition also results in elevated allergen-induced B cell IgE production seen mice then the significance of this must also be established and balanced against any therapeutic benefits. Such problems may be somewhat overcome by local administration to the lung through inhaled delivery and short-term treatments but it remains to be seen whether this potential repression of T regulatory cell function or possible elevation in IgE would be tolerable in the context of oral or long-term therapeutic administration.
Is there a real future for PI3K inhibitors in respiratory disease? The suitability of selective PI3K inhibitors, as with many potential therapeutic targets, depends on a balance of expression, function, disease relevance, toxicity profile and tolerance within the proposed disease. The potential hurdles of selective PI3K inhibition are exemplified by the lack of progression from in vivo models and early-stage human trials to late-stage development ]. However, in many respiratory diseases, current therapies are inadequate resulting in considerable unmet medical needs such as in severe asthma, COPD, CF and IPF. The data available clearly show that selective inhibition of PI3Kd and g is effective at controlling both adaptive and innate immune responses in disease models (Figure 3) .
The potential side effects of selective PI3Kd and/ or g inhibition will be an important determinant of their therapeutic and disease indication potential. In conditions such as mild to moderate asthma, which is not generally considered life threatening, the hurdle for side effect profiles is set very high. However, for conditions such as CF and IPF which are generally progressive and where little effective pharmacological therapy is available, side effect profiles may be clinically more acceptable. Short-term application may be suitable for those where toxicity profiles and/or tolerance are poor,such as during exacerbations of severe asthma and COPD. Furthermore, local administration to the lung may provide some shelter from peripheral side effects in terms of impact on other organs in the body. Finally, we must admit that the precise signalling pathways and mechanisms by which these isoforms mediate many of their functions remain relatively unclear. Given the undoubted importance of the PI3Kd and g isoforms in leukocyte function and the development and orchestration of inflammatory responses in the lung, the elucidation of these pathways is likely to uncover further important potential therapeutic opportunities. Engelman, J.A., Luo, J. and Cantley, L.C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606619. 
